Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Foritinib
Synonyms
Therapy Description	Foritinib is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Foritinib		Foritinib succinate\|SAF189s\|SAF 189s\|SAF-189s	ALK Inhibitor 33 ROS1 Inhibitor 23	Foritinib is an ALK and ROS1 inhibitor that is able to penetrate the central nervous system, which potentially reduces tumor cell proliferation and tumor growth (PMID: 32918045).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 7 of 7 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ROS1 rearrange	lung non-small cell carcinoma	sensitive	Foritinib	Phase II	Actionable	In a Phase II trial, Foritinib treatment led to an 89% (65/73, 65 partial responses (PR)) objective response rate (ORR), median duration of response (mDOR) of 20.7 mo, and median progression-free survival (mPFS) of 22.1 mo in ROS1 inhibitor-naive non-small cell lung cancer patients harboring a ROS1 rearrangement, including a 92.3% (24/26) ORR in patients with CNS lesions, and a 40% (10/25, 10 PR) ORR, mDOR of 7.0 mo, and mPFS of 5.5 mo in patients who received prior crizotinib (PMID: 39059398; NCT04237805).	39059398
ALK rearrange	lung non-small cell carcinoma	predicted - sensitive	Foritinib	Phase Ib/II	Actionable	In a Phase I/II trial, Foritinib was well tolerated in ALK-positive non-small cell lung cancer patients, and resulted in a disease control rate (DCR) of 100% and median progression-free survival (PFS) of 33.1 mo in ALK inhibitor (ALKi)-naive and 22.1 mo in ALKi-pretreated patients in Phase I, and a DCR of 98.1% and 88.5%, and objective response rate of 92.3% and 65.4%, in ALKi-naive or crizotinib-pretreated patients, respectively, in Phase II (J Clin Oncol 40, 2022 (suppl 16; abs 9076); NCT04237805).	detail...
ROS1 D2033N	Advanced Solid Tumor	predicted - sensitive	Foritinib	Preclinical - Biochemical	Actionable	In a preclinical study, Foritinib inhibited the kinase activity of a transformed cell line expressing ROS1 D2033N in culture (PMID: 32918045).	32918045
ROS1 G2032R	Advanced Solid Tumor	predicted - sensitive	Foritinib	Preclinical - Biochemical	Actionable	In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045).	32918045
ROS1 L2026M	Advanced Solid Tumor	predicted - sensitive	Foritinib	Preclinical - Biochemical	Actionable	In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 L2026M in culture (PMID: 32918045).	32918045
ROS1 S1986F	Advanced Solid Tumor	predicted - sensitive	Foritinib	Preclinical - Biochemical	Actionable	In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 S1986F in culture (PMID: 32918045).	32918045
ROS1 S1986Y	Advanced Solid Tumor	predicted - sensitive	Foritinib	Preclinical - Biochemical	Actionable	In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 S1986Y in culture (PMID: 32918045).	32918045

Showing 1 to 7 of 7 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Additional content available in CKB BOOST